Compare Biogen Inc (BIIB) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Kroger Co — how do they compare? Biogen Inc trades at $192.49 (market cap $28.34B), while Kroger Co trades at $58.75 (market cap $35.99B). The key difference: Kroger Co is the larger of the two by market cap, and Kroger Co pays a 2.45% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KR | |
|---|---|---|
Market Cap | $28.34B | $35.99B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $75.60 |
52-Week Low | $122.68 | $55.53 |
Enterprise Value | $30.62B | $56.08B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Kroger (KR) trades at $59.31, down 2.03% today, with technical indicators showing bearish momentum. The company maintains stable revenue around $147B with improving net margins (1.81% in 2025) and recently announced a $1.65B acquisition of Giant Eagle to expand Midwest presence. Strong cash flow generation ($2.08B net in 2025) supports dividend payments and strategic investments.
Kroger presents a mixed outlook with attractive valuation metrics (P/S 0.26) and analyst consensus target of $68.63 offering 16% upside potential. However, competitive pressures, recent earnings miss, and bearish technical signals warrant caution. The Giant Eagle acquisition provides growth opportunity but integration risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
